Big Pharma Has Raised The Prices Of 3,400 Drugs So Far This Year

| July 29, 2019

article image
In the first half of 2019, major pharmaceutical companies have raised the price of 3,400 different medications, with several dozen of those price increases being in the triple digit percentage. The average cost has increased by more than 4 times the rate of inflation, and the only reason this is happening is because they know they can get away with it. Ring of Fire’s Farron Cousins discusses this.

Spotlight

EvergreenHealth

EvergreenHealth, a public hospital district, is an integrated health care system offering a breadth of services and programs that is among the most comprehensive in the region. In addition to the 318-bed acute care hospital on EvergreenHealth’s main campus in Kirkland, which includes 24-hour Level III trauma emergency care and critical care, EvergreenHealth provides primary, urgent, and specialty care along with a 24/7 emergency department at its satellite EvergreenHealth Redmond Medical Center.

OTHER ARTICLES

Tips for Managing Chronic Pain Beyond Prescription Painkillers

Article | February 17, 2020

Painkillers like Oxycontin, Percocet, and Vicodin, have been prescribed by primary physicians, surgeons, dentists, and other healthcare providers to patients suffering from varying levels of pain. Though these medications have proven to be an effective source of pain relief, they have also proven to be highly addictive. In fact, it has even been reported that there are more cases of a drug overdose and deaths from prescription painkillers than heroin or cocaine. While there are a number of factors that play into this opioid epidemic, educating doctors and patients on alternative solutions to managing chronic pain is a great place to start combatting this nationwide crisis.

Read More

As Pandemic Continues, Rafael Pharmaceuticals Enrolls Patients in Phase III Pancreatic Cancer Trial

Article | April 17, 2020

That simple truth about the severity of the disease is one of the reasons that Rafael Pharmaceuticals is slowly continuing with a Phase III trial in metastatic pancreatic cancer during the COVID-19 pandemic. While many companies have paused enrollment in clinical trials during the outbreak, Cranbury, N.J,-based Rafael opted to continue to enroll patients in its Phase III AVENGER 500 study of its lead compound CPI-613 (devimistat) in combination with modified Folfirinox (mFFX) as first-line therapy for the disease. Sanjeev Luther, president and chief executive officer of Rafael Pharmaceuticals, told BioSpace that the company made the decision to continue to enroll the trial, which was 75% filled, due to the short timeline patients with metastatic pancreatic cancer have. After discussing the matter of the trial with the company’s leadership team, Luther said they felt comfortable leaving the decision of whether or not the trial should continue to the conducting institute.

Read More

Clinical Supply Availability & Speed to Study Start-Up

Article | March 26, 2020

If you’re part of a clinical study team racing a new product to commercialization, you likely live by these two simple rules: time is money, and the first one to market wins. But just because it’s simple doesn’t mean it’s easy. That ticking clock is background noise to the responsibilities of regulations, study protocols, supply chains, and patient recruitment — all the details that must be worked out before a study can even begin. The pressure is always there. The longer it takes for a study to start, the longer it takes to complete.

Read More

Do Clinical Trial Delays Mean Trouble for Pharmaceutical Stocks?

Article | April 1, 2020

Pharmaceutical stocks have been somewhat of a safe haven for investors as the coronavirus outbreak spread from China to the rest of the world. But as the pandemic deepened, now resulting in more than 782,000 cases worldwide, even these "safer" companies are beginning to feel the effects. The U.S. is now the coronavirus epicenter, with the most cases -- more than 161,000 as of today. Initial concerns for drugmakers had to do with the supply of active pharmaceutical ingredients, which often come from China. The worry was that pharmaceutical companies wouldn't be able to produce enough of their drugs for patients.

Read More

Spotlight

EvergreenHealth

EvergreenHealth, a public hospital district, is an integrated health care system offering a breadth of services and programs that is among the most comprehensive in the region. In addition to the 318-bed acute care hospital on EvergreenHealth’s main campus in Kirkland, which includes 24-hour Level III trauma emergency care and critical care, EvergreenHealth provides primary, urgent, and specialty care along with a 24/7 emergency department at its satellite EvergreenHealth Redmond Medical Center.

Events